Merck Concludes $3.4bn SpringWorks Acquisition
Deal News | Jul 02, 2025 | EIN
Merck KGaA has successfully completed the acquisition of SpringWorks Therapeutics for an enterprise value of $3.4 billion. This acquisition, initially announced in April 2025, follows regulatory approvals and fulfillment of closing conditions. Merck aims to improve its financial standing as the acquisition is expected to contribute to its revenues immediately and become accretive to earnings per share by 2027. Through this acquisition, Merck will integrate SpringWorks' two FDA-approved products, Ogsiveo and Gomekli, both targeting rare tumours with limited treatment options. The European Medicines Agency's Committee for Medicinal Products for Human Use also recommended these treatments for approval mid-2025. Belén Garijo, Merck's executive board chair and CEO, emphasized this acquisition as a pivotal shift for Merck's healthcare segment and reasserted the company's commitment to mergers and acquisitions. The merger marks Merck’s largest acquisition in nearly two decades within its healthcare sector. With the transaction's completion, SpringWorks' shares will stop trading on Nasdaq, with shareholders being compensated with $47 per share in cash by Merck.
Sectors
- Pharmaceuticals
- Biotechnology
Geography
- Germany – Merck KGaA, the acquiring company, is headquartered in Germany.
- United States – SpringWorks Therapeutics, the target company, is based in the United States, and its products are approved by the FDA for the U.S. market.
Industry
- Pharmaceuticals – The acquisition involves two FDA-approved drugs for rare tumours developed by SpringWorks Therapeutics, which align with the pharmaceutical industry's focus on innovative treatments.
- Biotechnology – SpringWorks Therapeutics' development of novel therapeutics targeting rare tumours fits within the biotechnology sector, which focuses on biotech advancements and medical innovations.
Financials
- $3.4 billion – The enterprise value at which Merck KGaA acquired SpringWorks Therapeutics.
- $47 per share – The cash value paid to SpringWorks Therapeutics shareholders by Merck for each share.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Merck KGaA | Acquiring Company | Company | A leading global science and technology company focused on healthcare, performance materials, and life sciences. |
| SpringWorks Therapeutics | Target Company | Company | A biopharmaceutical company focused on developing medicines for patients with severe rare diseases and cancer. |
| Beln Garijo | Executive Board Chair and CEO | Person | Chair and Chief Executive Officer of Merck KGaA, overseeing the strategic direction and global operations of the company. |
| Abbisko Therapeutics | Other Company | Company | Partnered with Merck for the development of pimicotinib, a treatment aimed at tenosynovial giant cell tumour patients. |